Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: puborectalis who wrote (104440)	5/10/2000 11:06:00 PM
From: puborectalis	Respond to of 108040

CMRC,TXN positive comments.............Talking Stocks: Geddes Commerce One, Celgene sound; be careful with Exodus; hold AT&T May 10, 2000: 4:20 p.m. ET NEW YORK (CNNfn) - Annette Geddes, portfolio manager for M.D. Sass, said Wednesday that Commerce One was overvalued in its heyday, but is fundamentally strong, that Exodus is sound as long as it keeps attracting customers, and that Celgene is a good biotech buy. Every day at 1 p.m. ET, CNNfn viewers are invited to call in to the "Talking Stocks" segment and ask equities questions of the guest expert. The toll-free number is: 800-304-FNET. Click here to send your stock questions to tomorrow's guest. Name: Akber, Chicago Question: Commerce One (CMRC: Research, Estimates). I bought this stock at 276; now it's at 42. Will it bounce back to the 300 level? What do you think of this company's future growth and earnings? Answer: Commerce One is in the Internet B2B space. They're one of the three strong companies in the niche, but the stock was overvalued at 276, and now, at 42, it's too cheap to sell. Whether it will bounce back to 300 depends on the market. But when the correction is over and investors return to the Internet names, CMRC has a very viable business in this category. Fundamentally it's a solid company. Name: Connie (location unknown) Question: Exodus (EXDS: Research, Estimates). I bought 20 shares of exodus at 81. Now the stock is down to 74. What is your short- and long- term recommendation on this one? Answer: Exodus is the leading company in Web hosting. They maintain very large server farms; and since it's more financially attractive for companies to outsource Web hosting, they have a solid business going forward. The risk in the stock is the company's heavy debt load, because Web hosting is a very capital-intensive business. We prefer stocks with less financial risk, but as long as Exodus can maintain its customer growth going forward, there shouldn't be any near-term financial risk. Name: Jim, Pennsylvania Question: Texas Instruments (TXN: Research, Estimates). What is the chip cycle for a company? When I hear that the chip cycle is good for two-to-three years, but hear that the Internet/telecom cycle is good for five to ten years, it seems a contradiction since chips of a proprietary nature should evolve with the sector they supply. Answer: We like TXN because it's evolving into an Internet telecom play and, as such, has a little longer time horizon in its product cycle, which makes TXN a more stable growth stock going forward. Name: Jim, California Question: AT&T (T: Research, Estimates). I own 600 shares at 47. Buy more, sell or hold? Answer: AT&T is at best a hold at this point. It's not a sell because there could be a corporate event that could bolster the stock, like AT&T selling Excite@Home (ATHM: Research, Estimates) shares. The problem is they've lost the tech lead, and until management can prove they're at the cutting edge, there are more attractive stocks in this space. The fact that it's so widely owned and has done so poorly recently means that it will be under distribution for a while unless there's a new catalyst of a fundamental nature. Name: Qui, Connecticut Question: Celgene (CELG: Research, Estimates). What is the future (three-to-five years) for Celgene stock? Is it a good stock for long term? Would you recommend buying now? Answer: Celgene is a biotech stock that has taken an old drug with dreadful side effects and adapted it for use in the treatment of other diseases, such as cancer therapy and epilepsy. We think there's a flow of positive announcements in other drugs going forward, and we would definitely own it for the long term. Yes, we would buy now. CNNfn welcomes your e-mail questions for our "Talking Stocks" guest. Please include your first name, state and one stock question per e-mail. Please keep in mind, "Talking Stocks" is for specific stock questions only. If you do not see an answer to your e-mail here, it is because our guest does not cover the company.